As can be seen in Figure 3A, a positive correlation was observed for EGFR and PD-L1 in THYM, PRAD, diffuse large B-cell lymphoma (DLBC) and PAAD (Rho > 0.6), followed by THCA (Rho > 0.5) and breast-invasive carcinoma, luminal A (BRCA LumA), cholangiocarcinoma (CHOL), liver hepatocellular carcinoma (LIHC), KIRC and BRCA-basal (Rho > 0.4). Here, EGFR is linked to prostate adenocarcinoma.